You have 9 free searches left this month | for more free features.

pemetrexed

Showing 1 - 25 of 527

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • (no location specified)
Jan 18, 2023

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Pemetrexed
  • (no location specified)
Mar 27, 2023

NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 16, 2023

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Pemetrexed
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)

Recruiting
  • Non Small Cell Lung Cancer
  • Mesothelioma
  • Pemetrexed
  • 's-Hertogenbosch, Netherlands
  • +4 more
Sep 9, 2022

Leptomeningeal Metastasis Trial in Changchun (Pemetrexed, Radiotherapy)

Recruiting
  • Leptomeningeal Metastasis
  • Pemetrexed
  • Radiotherapy
  • Changchun, Jilin, China
    The First Hospital of Jilin University
Jun 8, 2022

Non-Small-Cell Lung Carcinoma Trial (biological, drug, dietary supplement)

Active, not recruiting
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • (no location specified)
Aug 16, 2022

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

Carcinoma, Non-Small-Cell Lung Trial in Beijing (HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar,

Recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • HLX10, an engineered anti-PD-1 antibody
  • +3 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences (CAMS)
Apr 29, 2022

Adenocarcinoma of Lung, NSCLC Trial in Rolling Meadows (LP-300, Pemetrexed, Carboplatin)

Not yet recruiting
  • Adenocarcinoma of Lung
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 8, 2022

Mesothelioma Trial in Houston (Pemetrexed, Cisplatin)

Terminated
  • Mesothelioma
  • Houston, Texas
    Baylor St Lukes
Mar 15, 2022

Urothelial Carcinoma, Metastatic Cancer Trial in Houston (Pemetrexed, Zimberelimab, Etrumadenant)

Not yet recruiting
  • Urothelial Carcinoma
  • Metastatic Cancer
  • Pemetrexed
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Nov 28, 2022

Lung Cancer Trial in Houston (AMG 510, Cisplatin, Carboplatin)

Recruiting
  • Lung Cancer
  • AMG 510
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

NSCLC, Mesothelioma, Bladder Cancer Trial in Augusta (Bosutinib, Pemetrexed)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • +7 more
  • Augusta, Georgia
    Augusta University Georgia Cancer Center
Jun 10, 2022

Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Brain Metastases
  • Guangzhou, Guangzhou, China
    Li-Kun Chen
Nov 13, 2022

CNS Lymphoma Trial in Zhengzhou (ICP-022, Pemetrexed)

Recruiting
  • Central Nervous System Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jan 28, 2022

Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)

Terminated
  • Non Small Cell Lung Cancer
  • Mesothelioma
  • Pemetrexed
  • 's-Hertogenbosch, Netherlands
  • +4 more
May 9, 2022

Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)

Completed
  • Non Small Cell Lung Cancer
  • Mesothelioma
  • Pemetrexed
  • 's-Hertogenbosch, Netherlands
  • +4 more
May 9, 2022

Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4 Trial in Boston (Granulocyte-Macrophage

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • +4 more
  • Boston, Massachusetts
    Tufts Medical Center
Oct 3, 2022

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

Glioma, Brain Metastases Trial in Shanghai (Autologous progenitor expansion -T, pemetrexed)

Recruiting
  • Glioma
  • Brain Metastases
  • Autologous progenitor expansion -T
  • pemetrexed
  • Shanghai, Shanghai, China
    Fudan University Pudong Medical Center
Jul 12, 2022

NSCLC Trial in Gyeonggi-do, Incheon, Seoul (Lazertinib, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Gyeonggi-do, Korea, Republic of
  • +5 more
Jul 25, 2022

NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 19, 2022

Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)

Active, not recruiting
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • Nagoya, Aichi, Japan
  • +9 more
Jan 23, 2023